About Dynein light chain Tctex-type 4
Dynein light chain Tctex-type 4 (DYNLT4) is a protein
from Homo sapiens identified by UniProt accession
Q5JR98, 221 residues long.
MolForge cross-references it against 0 known binders and
60 disease associations.
Target properties
| Protein name | Dynein light chain Tctex-type 4 |
| UniProt accession | Q5JR98 |
| Gene | DYNLT4 |
| Organism | Homo sapiens |
| Length | 221 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (60)
Diseases linked to this target (Open Targets).
- Neurodevelopmental disorder · score 0.11
- Blackfan-Diamond anemia · score 0.09
- apolipoprotein B measurement · score 0.09
- hereditary persistence of fetal hemoglobin-sickle cell disease syndrome · score 0.07
- primary familial polycythemia due to EPO receptor mutation · score 0.07
- Alpha-thalassemia - intellectual disability syndrome linked to chromosome 16 · score 0.07
- alpha thalassemia-intellectual disability syndrome type 1 · score 0.07
- alpha-thalassemia-myelodysplastic syndrome · score 0.06
- hemoglobin E-beta-thalassemia syndrome · score 0.06
- delta-beta-thalassemia · score 0.06
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q5JR98-F1 | alphafold | PREDICTED | 73.28 | — |
Amino-acid sequence (221 residues)
MASRPLPPGR QEEENAKDSG RKPSPVRPRG CLPSIDEARP AGPGPAPASR RGSMLGLAAS FSRRNSLVGP GAGPGGQRPS LGPVPPLGSR VSFSGLPLAP ARWVAPSYRT EPVPGERWEA ARAQRALEAA LAAGLHDACY SSDEAARLVR ELCEQVHVRL RELSPPRYKL VCSVVLGPRA GQGVHVVSRA LWDVARDGLA SVSYTNTSLF AVATVHGLYC E
Explore Dynein light chain Tctex-type 4 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets